Automated insulin system outperforms standard care in managing type 1 diabetes in youth

Automated insulin delivery (AID) systems significantly improve glycemic control in children and young adults with type 1 diabetes and elevated glycated hemoglobin (HbA1c) levels, according to a study.

The randomized controlled trial included 80 patients between the ages of 7 to 25 years, who were randomly assigned to either use the MiniMed 780G AID system or receive standard diabetes care, including multiple daily injections or non-automated pump therapy.

After 13 weeks, the AID group showed a significant reduction in HbA1c levels, dropping from 10.5% to 8.1%, while the control group saw no improvement. In addition, those using AID spent more time in the target glucose range (70 to 180 mg/dL) compared to the control group. No severe hypoglycemia or diabetic ketoacidosis events occurred in the AID group, while the control group experienced 1 case of severe hypoglycemia and two of diabetic ketoacidosis.

Reference
Boucsein A, Zhou Y, Michaels V, et al. Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c. NEJM Evid. 2024;3(10):EVIDoa2400185. doi: 10.1056/EVIDoa2400185. Epub 2024 Sep 24. PMID: 39315863.